Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Non-human Molecule Is Absorbed by Eating Red Meat According to Study by UCSD Researchers

30.09.2003


A non-human, cellular molecule is absorbed into human tissues as a result of eating red meat and milk products, according to a study by researchers at the University of California, San Diego (UCSD) School of Medicine, published online the week of September 29, 2003 in Proceedings of the National Academy of Sciences. The researchers also showed that the same foreign molecule generates an immune response that could potentially lead to inflammation in human tissues.

Several previous studies have linked ingestion of red meat to cancer and heart disease, and possibly to some disorders involving inflammation. However, that research has primarily focused on the role of red-meat saturated fats and on products that arise from cooking. The UCSD study is the first to investigate human dietary absorption of a cell-surface molecular sugar called N-glycolylneuraminic acid (Neu5Gc), which is found in non-human mammals. Not produced in humans, Neu5Gc occurs naturally in lamb, pork and beef, the so-called “red meats”. Levels are very low or undetectable in fruits, vegetables, hen’s eggs, poultry and fish.

Conducting laboratory studies with human tissue, followed by tests in three adult subjects, the UCSD team provided the first proof that people who ingest Neu5Gc absorb some of it into their tissues. In addition, they demonstrated that many humans generate an immune response against the molecule, which the body sees as a foreign invader.



The study’s senior author, Ajit Varki, M.D., UCSD professor of medicine and cellular and molecular medicine, and co-director of the UCSD Glycobiology Research and Training Center, said that although it is unlikely that the ingestion of Neu5Gc alone would be primarily responsible for any specific disease, “it is conceivable that gradual Neu5Gc incorporation into the cells of the body over a lifetime, with subsequent binding of the circulating antibodies against Neu5Gc (the immune response), could contribute to the inflammatory processes involved in various diseases.”

He added that another potential medical barrier related to Neu5Gc might occur in organ transplantation.

“Over the past decade, the number of patients waiting for organ transplantation has more than tripled, with little increase in the number of donor organs. This has led to an exploration of using animal organs for transplantation into humans, a process called xenotransplantation,” Varki said. “However, the leading donor candidate is the pig, an animal in which Neu5Gc happens to be very common. The current study raises the possibility that human antibodies against Neu5Gc might recognize the Neu5Gc in the pig organ and facilitate its rejection.”

In describing the research approach taken by his team, Varki explained that humans do not produce Neu5Gc because they lack the gene responsible for its production.** And yet, other researchers have reported small amounts of Neu5Gc in human cancer tissues.

To verify the existence of Neu5Gc in human cancers, Varki’s collaborator, Elaine Muchmore, M.D., UCSD professor of medicine and associate chief of staff for education at the San Diego VA Healthcare System, developed an antibody that would be attracted by, and bind to Neu5Gc on tissue samples. The antibody was purified by Pam Tangvoranuntakul, B.S., the study’s first author and a Ph.D. student in Varki’s lab.

Working with Nissi Varki, M.D., UCSD professor of pathology and medicine, Tangvoranuntakul found that the antibody stained not only human cancers, but also some healthy human tissues. They found that small amounts of Neu5Gc were present in blood vessels and secretory cells, such as the mucous membranes. A further chemical analysis by Sandra Diaz, a Varki research associate, confirmed the presence of Neu5Gc in human tissue.

Meanwhile, an analysis of healthy human tissue by postdoctoral fellow Pascal Gagneux, Ph.D., and Tangvoranuntakul determined that most people had circulating antibodies in the blood that recognized Neu5Gc, and thus could potentially initiate an inflammatory immune response.

In the absence of any known molecular mechanism that would produce Neu5Gc in humans, the group reasoned that the small amounts of Neu5Gc found in human tissue could arise from human ingestion of Neu5Gc in dietary sources. Postdoctoral fellow Muriel Bardor, Ph.D., showed that when human cells in culture were exposed to Neu5Gc, they easily absorbed and incorporated it onto their own surfaces.

However, to study the possibility of dietary absorption, it was necessary to carry out an ingestion study in healthy people. Because the researchers were hesitant to give a potentially harmful substance to humans, Ajit Varki volunteered to be the first subject, followed by Muchmore and Gagneux.

When the three volunteers drank Neu5Gc purified from pork sources and dissolved in water, there were no immediate ill effects. An analysis of the volunteers’ urine, blood, serum (the clear liquid that can be separated from clotted blood), hair and saliva, both before ingestion and regularly for several days after, determined that the human body eliminates most of the Neu5Gc, but retains and metabolically absorbs small amounts of the foreign sugar. At approximately two days following ingestion, the Neu5Gc levels were two to three times the baseline level prior to ingestion. By four to eight days following ingestion, the levels had dropped nearly to baseline.

The authors cautioned that a causal relationship between Neu5Gc expression in human tissues with any human disease would be premature and scientifically speculative at best. Instead, they said their findings point to the need for population-level analyses of the presence of Neu5Gc in human tissues in relationship to disease incidence, and the mechanisms of human incorporation and antibody response against this sugar.

The study was supported by grants to Varki from the National Institutes of Health (NIH) and the G. Harold and Leila Y. Mathers Charitable Foundation. Some human studies were done in the UCSD General Clinical Research Center, which is also supported by the NIH.

Sue Pondrom | UCSD
Further information:
http://health.ucsd.edu/news/2003/09_29_Varki.html

More articles from Life Sciences:

nachricht MicroRNA helps cancer evade immune system
19.09.2017 | Salk Institute

nachricht Ruby: Jacobs University scientists are collaborating in the development of a new type of chocolate
18.09.2017 | Jacobs University Bremen gGmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

Im Focus: Fast, convenient & standardized: New lab innovation for automated tissue engineering & drug

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...

Im Focus: Silencing bacteria

HZI researchers pave the way for new agents that render hospital pathogens mute

Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...

Im Focus: Artificial Enzymes for Hydrogen Conversion

Scientists from the MPI for Chemical Energy Conversion report in the first issue of the new journal JOULE.

Cell Press has just released the first issue of Joule, a new journal dedicated to sustainable energy research. In this issue James Birrell, Olaf Rüdiger,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

New quantum phenomena in graphene superlattices

19.09.2017 | Physics and Astronomy

A simple additive to improve film quality

19.09.2017 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>